Trial · NCT04343235
Postpartum Management of Gestational Hypertensive Disorders Using Furosemide
NCT04343235, Phase 4, Terminated, Wright State University; results first posted 2023-10-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Postpartum Management of Gestational Hypertensive Disorders Using Furosemide. Trials, record NCT04343235. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04343235
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Postpartum Management of Gestational Hypertensive Disorders Using Furosemide
- NCT number
- NCT04343235
- Status
- Terminated
- Phases
- Phase 4
- Enrollment
- 13 participants, actual
- Lead sponsor
- Wright State University
- Conditions
- Hypertension, Pregnancy-Induced
- Interventions
- furosemide, labetalol
- First posted
- 2020-04-13
- Last updated
- 2023-10-23
- Results first posted
- 2023-10-23
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of Dose for Antihypertensive Therapy | Change in dose of hypertensive therapy from randomization until hospital discharge (up to 7 days) | number of patients who require a change in the dose of labetalol to control BP |
| Secondary | Change of Gestational Hypertensive Disorder Symptoms (Systolic BP) | Average systolic blood pressure for Day 0, Day 1, and Day 2 | average systolic blood pressure reading on Day 0, Day 1, and Day 2 |
| Secondary | Change of Gestational Hypertensive Disorder Symptoms (Mean Arterial Pressure) | Average mean arterial pressure on Day 0, Day 1, and Day 2 | average mean arterial pressure reading on Day 0, Day 1, and Day 2 |
| Secondary | Change of Gestational Hypertensive Disorder Symptoms (Diastolic BP) | Average diastolic blood pressure on Day 0, Day 1, and Day 2 | average diastolic blood pressure reading on Day 0, Day 1, and Day 2 |
| Secondary | Hospital Length of Stay | Number of days of hospital stay from randomization to discharge | days in hospital after delivery |
| Secondary | Breastfeeding Status | at 1 week postpartum visit | breastfeeding continuation after discharge |
| Secondary | Hospital Readmission | up to 14 days after discharge | readmission for hypertension management |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change of Dose for Antihypertensive Therapy | Change in dose of hypertensive therapy from randomization until hospital discharge (up to 7 days) | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Change of Gestational Hypertensive Disorder Symptoms (Systolic BP) | Average systolic blood pressure for Day 0, Day 1, and Day 2 | mm of mercury | MEAN | |
| SECONDARY | Change of Gestational Hypertensive Disorder Symptoms (Mean Arterial Pressure) | Average mean arterial pressure on Day 0, Day 1, and Day 2 | mm of mercury | MEAN | |
| SECONDARY | Change of Gestational Hypertensive Disorder Symptoms (Diastolic BP) | Average diastolic blood pressure on Day 0, Day 1, and Day 2 | mm of mercury | MEAN | |
| SECONDARY | Hospital Length of Stay | Number of days of hospital stay from randomization to discharge | days | MEAN | |
| SECONDARY | Breastfeeding Status | at 1 week postpartum visit | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Hospital Readmission | up to 14 days after discharge | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change of Dose for Antihypertensive Therapy | Labetalol + Furosemide | 3 | Participants | ||
| Change of Dose for Antihypertensive Therapy | Labetalol Only | 0 | Participants | ||
| Change of Gestational Hypertensive Disorder Symptoms (Systolic BP) | Labetalol + Furosemide | Day 0 | 138.4 | Standard Deviation 11.2 | mm of mercury |
| Change of Gestational Hypertensive Disorder Symptoms (Systolic BP) | Labetalol Only | Day 0 | 138.1 | Standard Deviation 9.4 | mm of mercury |
| Change of Gestational Hypertensive Disorder Symptoms (Systolic BP) | Labetalol + Furosemide | Day 1 | 134.9 | Standard Deviation 5.4 | mm of mercury |
| Change of Gestational Hypertensive Disorder Symptoms (Systolic BP) | Labetalol Only | Day 1 | 138.2 | Standard Deviation 8.5 | mm of mercury |
| Change of Gestational Hypertensive Disorder Symptoms (Systolic BP) | Labetalol + Furosemide | Day 2 | 135.2 | Standard Deviation 13.7 | mm of mercury |
| Change of Gestational Hypertensive Disorder Symptoms (Systolic BP) | Labetalol Only | Day 2 | 136.7 | Standard Deviation 6.0 | mm of mercury |
| Change of Gestational Hypertensive Disorder Symptoms (Mean Arterial Pressure) | Labetalol + Furosemide | Day 0 | 102.4 | Standard Deviation 10.7 | mm of mercury |
| Change of Gestational Hypertensive Disorder Symptoms (Mean Arterial Pressure) | Labetalol Only | Day 0 | 100.0 | Standard Deviation 9.2 | mm of mercury |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Labetalol + Furosemide | 6 | |
| Overall Study | STARTED | Labetalol Only | 7 | |
| Overall Study | COMPLETED | Labetalol + Furosemide | 3 | |
| Overall Study | COMPLETED | Labetalol Only | 5 | |
| Overall Study | NOT COMPLETED | Labetalol + Furosemide | 3 | |
| Overall Study | NOT COMPLETED | Labetalol Only | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Labetalol + Furosemide | 0 | 6 |
| Total, all-cause mortality | Labetalol Only | 0 | 7 |
| Total, other adverse events | Labetalol + Furosemide | 0 | 6 |
| Total, other adverse events | Labetalol Only | 0 | 7 |
| Total, serious adverse events | Labetalol + Furosemide | 0 | 6 |
| Total, serious adverse events | Labetalol Only | 0 | 7 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons5
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Labetalol + Furosemide vs Labetalol Only: Change of Dose for Antihypertensive Therapy | Trial comparisons |
| Labetalol + Furosemide vs Labetalol Only: Breastfeeding Status | Trial comparisons |
| Labetalol + Furosemide vs Labetalol Only: Hospital Readmission | Trial comparisons |
| Labetalol + Furosemide vs Labetalol Only: deaths from any cause | Trial comparisons |
| Labetalol + Furosemide vs Labetalol Only: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04343235
GET https://conductscience.org/api/trials/v1/NCT04343235/results?page=2